Fosun Pharma raises $512 million, while Dynasty Reit cancels IPO

The market remains challenging for new listings and both deals attract modest demand from international investors, with Fosun forced to reallocate shares to retail investors to make up for the lack of institutional interest.
<div style="text-align: left;">
Fosun's Shanghai headquarters
</div>
<div style="text-align: left;"> Fosun's Shanghai headquarters </div>

Shanghai Fosun Pharmaceutical has raised HK$3.97 billion $512 million after pricing its Hong Kong initial public offering at the bottom of the indicated range.

The company, which is already listed in Shanghai, will be the largest new listing in Hong Kong in three months, but it is still unlikely to give issuers in the pipeline the reassurance they are looking for with regard to investor appetite for IPOs.

A key reason for that is that the majority of the institutional demand came from China-based accounts. And even though investors were told on Friday last week that the deal was fully covered, the bookrunners ended up...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222